Creatinine is an endogenous by-product of muscle metabolism. Clinical laboratory measurement of this waste product is used for the assessment of glomerular filtration rate (GFR) that further defines kidney function of patient. Most of the routine creatinine assays that are in current use include Jaffe’s kinetic methods and enzymatic methods. The global market is segmented on the basis of test type, product, sample, and end use.
High prevalence of renal disorders is a major factor driving the market growth globally. As per estimates of American Kidney Fund, kidney disorders was ninth leading cause of death in the U.S. Approximately 31 million of U.S. population suffers with Chronic Kidney Disease (CKD). Moreover, according to the Global Burden of Disease (GBD) estimates, there were around 1.2 million deaths due to cardiovascular disorders in 2015, wherein cardiovascular disorders were stimulated by reduced glomerular filtration rate.This high prevalence has promoted the companies and health organizations to invest in the development of robust renal disorders measurement tools.
The demand of creatinine measurement kits and reagents is also supplemented by an increase in incidence of other chronic disorders that impact the kidney function. For instance, diabetes and high blood pressure leads to almost 44% and 29% of total kidney failure cases respectively. The market growth is further boosted by an escalation in global geriatric population which is more prone to renal disorders, supportive government regulations in order to promote renal health, and advent of monitoring technologies. One of such promising technological advancements include employment of point of care creatinine measuring devices which serve as a rapid method. This aids in the eradication of requirement of skilled analytical personnel to accomplish complicated monitoring technique.
Furthermore, in order to enhance the market growth, National Kidney Disease Education Program’s laboratory working group collaborated with the European Federation of Clinical Chemistry, Laboratory Medicine & International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) to form the Creatinine Standardization Program. This initiative by government agencies resulted in the reduction of interlaboratory variation in creatinine assay calibration which in turn enhanced the accuracy of glomerular filtration rate estimation. Such initiatives assist healthcare professionals in detection and treatment of several renal diseases, thereby improving the patient outcomes.
However, shifting preferences of healthcare professionals towards novel techniques, that include the identification of renal dysfunction biomarkers, and lack of predictive value obtained by creatinine measurement techniques is expected to hamper the market growth.
Major players operating in the creatinine measurement industry include BioAssay Systems, Abcam plc, Arbor Assays, Thermo Fisher Scientific, Randox Laboratories Ltd., Sentinel CH. SpA, DiaSys Diagnostic Systems GmbH, MedTest Holdings, Inc. (Pointe Scientific, Inc.), Abbexa Ltd., and General Atomics, Inc. (Diazyme Laboratories, Inc.). These industrial players are engaged in the development of kits and reagents along with the introduction of novel techniques for successful creatinine detection.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."